Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe

Annals of Oncology

Volumn 17, Issue 7, 2006, Pages 1134-1140

  Barkholt, Lisbeth ^a   Bregni, M ^b   Remberger, M ^a   Blaise, D ^c   Peccatori, J ^b   Massenkeil, G ^d   Pedrazzoli, P ^e   Zambelli, A ^f   Bay, J O ^g   Francois, S ^h   Martino, R ⁱ   Bengala, C ^j   Brune, M ^k   Lenhoff, S ^l   Porcellini, A ^m   Falda, M ⁿ   Siena, S ^e   Demirer, T ^o   Niederwieser, D ^p   Ringden O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c INSTITUT PAOLI CALMETTES   (France)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f IRCCS   (Italy)

^g CENTRE JEAN PERRIN   (France)

^h ANGERS UNIVERSITY HOSPITAL   (France)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j UNIVERSITY OF PISA   (Italy)

^k SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^l LUND UNIVERSITY HOSPITAL   (Sweden)

^m Ospedale PF Calvi Noale   (Italy)

ⁿ MOLINETTE HOSPITAL   (Italy)

^o ANKARA UNIVERSITY   (Turkey)

^p UNIVERSITY HOSPITAL LEIPZIG   (Germany)

more..

Author keywords

Allogeneic stem cell transplantation; Antitumour effect; Reduced intensity conditioning; Renal cell carcinoma

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; INTERLEUKIN 2; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DONOR; EUROPE; FOLLOW UP; HLA MATCHING; HUMAN; INCIDENCE; INFUSION; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MORTALITY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; SIBLING; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; CARCINOMA, RENAL CELL; CHIMERISM; EUROPE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PATIENT SELECTION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

EID: 33745588857     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl086     Document Type: Article

References (38)

1. Truitt RL, Shih C-Y, LeFever AV. Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in AKR mice with spontaneous leukaemia/lymphoma. Transplantation 1986; 41: 301-310.
2. Weiden PL, Fluornoy N, Thomas ED et al. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979; 300: 1068-1073.
3. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
4. Ringdén O, Labopin M, Gluckman E et al. Graft-versus-leukemia effect in allogeneic marrow recipients with acute leukaemia is maintained using cyclosporine A combined with methotrexate as prophylaxis. Bone Marrow Transplant 1996; 18: 921-929.
5. Kolb H-J, Schattenberg A, Goldman J et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
6. Eibl B, Schwaighhofer H, Nachbaur D et al. Evidence of graft-versus-tumour effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501-1508.
7. Ben-Yosef R, Or R, Nagler A et al. Graft-versus-tumour and graft-versus-leukaemia effect in patients with concurrent breast cancer and acute myeloid leukaemia. Lancet 1996; 348: 1242-1243.
8. Ueno NT, Rondón G, Mirza NQ et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986-993.
9. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
10. Zetterquist H, Hentschke P, Thörne A et al. A graft-versus-colonic cancer effect after allogeneic stem-cell transplantation. Bone Marrow Transplant 2001; 28: 1161-1166.
11. Bay JO, Fleury J, Choufi B et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: Results of five patients. Bone Marrow Transplant 2002; 30: 95-102.
12. Artz AS, van Besien K, Zimmerman T et al. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant 2005; 35: 253-260.
13. Gratwohl A, Baldomero H, Demirer T, Rosti G, Dini G, Ladenstein R, Urbano-Ispizua A. Hematopoetic stem cell transplantation for solid tumors in Europé. Ann Oncol 2004; 15: 653-660.
14. Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.
15. Hentschke P, Barkholt L, Uzunel M et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253-261.
16. Blaise D, Bay JO, Faucher C et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumours. Blood 2004; 103: 435-441.
17. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
18. Slavin S, Nagler A, Naparstek E et al. Non myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-763.
19. McSweeney P, Storb R. Mixed chimerism: Preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999; 5: 192-203.
20. Mattsson J, Uzunel M, Remberger M et al. Minimal residual disease is common after allogeneic stem cell transplantation in patients with B-cell chronic lymphocytic leukemia and may be controlled by graft-vs-host disease. Leukemia 2000; 14: 247-254.
21. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis. Bone Marrow Transplant 2001; 28: 909-915.
22. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001; 28: 1001-1011.
23. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma. Clin Cancer Res 2004; 10: 6302S-3S.
24. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995; 22: 42-60.
25. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271: 907-913.
26. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338: 1272-1278.
27. Yang JC, Haworth L, Sherry RM et al. A randomised trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
28. Motzer R, Michaelson MD, Reman BG et al. SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, demonstrated antitumor activity in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
29. Vogelzang NJ. Treatment options in metastatic renal carcinoma: An embrassment of riches. J Clin Oncol 2006; 24: 1-3.
30. Gommersall L, Hayne D, Lynch C et al. Allogeneic stem-cell transplantation for renal-cell cancer. Lancet Oncol 2004; 5: 561-567.
31. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumour effects. Blood 2001; 97: 3390-3400.
32. Le Blanc K, Remberger M, Uzunel M et al. A comparison of non-myeloablative versus reduced intensity conditioning for allogeneic stem cell transplantation. Transplantation 2004; 78: 1014-1020.
33. Peccatori J, Barkholt L, Demirer T et al. Prognostic factors for survival in patients with advanced renal cell cancer undergoing non-myeloablative allogeneic stem cell transplantation. Cancer 2005; 10: 2099-2103.
34. Harlin H, Artz AS, Mahowald M et al. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-y-producing T cells. Bone Marrow Transplant 2004; 33: 491-497.
35. Carnevale-Schianca F, Cignetti A, Capaldi A et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: Tumor-specific T-cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood Jan 2006; doi:10.1182/ blood-2005-10-3945.
36. Carlens S, Aschan J, Remberger M et al. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukemia. Bone Marrow Transplant 1999; 24: 629-635.
37. Spigel DR, Hainsworth JD, Sosman JA et al. Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter tiral. J Clin Oncol 2005; 23 (Suppl): 387 (Abstr. 4540).
38. Rini BI, Sosman JA, Motzer RJ. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Biology, clinical results and future development. B J Urol International 2005; 96: 286-290.